限局性または乏転移性前立腺がんの黒人またはアフリカ系アメリカ人患者のサバイバーシップ・ケアへの理解とアクセスを向上させるための、カスタマイズされたサバイバーシップ・ケア・プラン
十分なサービスを受けられていないアフリカ系アメリカ人の前立腺がん患者のアクセスを改善するための、カスタマイズされた生存者ケア計画でヘルスリテラシーに取り組む
This clinical trial compares the impact of a tailored survivorship care plan (SCP) to a standard SCP on the understanding of and access to survivorship care in black or African American patients with prostate cancer that has not spread to other parts of the body (localized) or that has spread from where it first started (primary site) to a limited number of places in the body (oligometastatic). SCPs summarize treatment history and recommendations for monitoring and maintaining health, and may also include potential long term effects of treatments received. The intention of a SCP is to help patients participate in their own health care. However, many patients have below basic levels of health literacy, meaning, they have a lower ability to obtain, communicate, process and understand basic health information and services to make health decisions. In fact, poor health literacy has been linked with worse quality of life in prostate cancer survivors. A tailored SCP includes the addition of an educational supplement based on lower reading and writing skills (low literacy) and may address health literacy barriers to understanding of treatment options and side effects. A standard SCP uses a template based on the American Society of Clinical Oncology (ASCO) guidelines for prostate cancer. A tailored SCP with low literacy educational supplements may be more effective compared to a standard SCP in improving understanding and access to survivorship care in black or African American patients with localized or oligometastatic prostate cancer.
調査の概要
状態
詳細な説明
PRIMARY OBJECTIVES:
I. Compare outcomes after patients receive usual care from their providers with a standard SCP and after patients receive tailoring of the SCP with the low literacy educational supplement.
II. To quantify the potential benefit of tailoring the care plan and the educational supplement.
III. Compare providers' assessment of patients':
IIIa. Health literacy; IIIb. Comprehension of survivorship care recommendations; IIIc. Understanding of long term and late effects from treatment; IIId. To measures obtained from patients.
OUTLINE: Patients are randomized to 1 of 2 groups.
GROUP I (INTERVENTION): Patients receive standard SCP during a provider visit and a tailored SCP with a low literacy educational supplement during a structured interview over 30-60 minutes.
GROUP II (CONTROL): Patients receive standard SCP using the prostate cancer ASCO template during a provider visit and undergo a structured interview over 30-60 minutes.
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前:Kerry L. Kilbridge, MD, MSc
- 電話番号:617-632-2429
- メール:Kerry_Kilbridge@DFCI.HARVARD.EDU
研究場所
-
-
Georgia
-
Atlanta、Georgia、アメリカ、30322
- 募集
- Emory University Hospital/Winship Cancer Institute
-
コンタクト:
- Sierra Williams
- 電話番号:404-778-4898
- メール:sierra.williams@emory.edu
-
主任研究者:
- Viraj Master, MD, PhD, FACS
-
Atlanta、Georgia、アメリカ、30303
- 募集
- Grady Memorial Hospital
-
コンタクト:
- Sierra Williams
- 電話番号:404-778-4729
- メール:sierra.williams@emory.edu
-
主任研究者:
- Viraj Master, MD, PhD, FACS
-
Atlanta、Georgia、アメリカ、30329
- 募集
- Atlanta VA Medical Center
-
コンタクト:
- Sierra Williams
- 電話番号:404-778-4729
- メール:sierra.williams@emory.edu
-
主任研究者:
- Mohammad Hajiha, MD
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Black and African American men who are disease-free after completing primary surgery and/or radiation treatment for localized or oligometastatic prostate cancer between 1 to 4 years prior to enrollment. (Race/ethnicity per medical records and self report)
- Patients who are still receiving adjuvant androgen deprivation therapy following primary radiation with non-palliative intent may be included
Exclusion Criteria:
- Dementia or cognitive impairment per provider clinical assessment
- Unable to give informed consent in the judgement of the patient's oncology provider
- Recurrent prostate cancer after primary treatment
- Less than 18 years of age at the time of informed consent
- Diagnosis of active second malignancy requiring treatment
- Individuals who are not able to clearly understand English since the outcome measures require understanding of English
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:支持療法
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Group I (standard SCP, tailored SCP)
Patients receive standard SCP during a provider visit and a tailored SCP with a low literacy educational supplement during a structured interview over 30-60 minutes. |
Ancillary studies Receive a low literacy educational supplement
他の名前:
Undergo a structured interview Receive standard SCP
他の名前:
Receive a tailored SCP
他の名前:
|
|
アクティブコンパレータ:Group II (standard SCP)
Patients receive standard SCP using the prostate cancer ASCO template during a provider visit and undergo a structured interview over 30-60 minutes. |
Ancillary studies Undergo a structured interview Receive standard SCP
他の名前:
Receive a tailored SCP
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Comprehension of survivorship care recommendations and prostate specific antigen surveillance
時間枠:At baseline and up to 3 month phone call
|
Comprehension will be scored as dichotomous variables, correct or incorrect. The proportion of patients who correctly understand after the standard survivorship care plan (SCP) compared to the proportion who correctly understand after the standard SCP + tailoring + educational support will be analyzed using a two-tailed Z-score test for equality of two proportions at a significance level of P < 0.05. |
At baseline and up to 3 month phone call
|
|
Comprehension of treatment side effects and late effects
時間枠:At baseline and up to 3 month phone call
|
Comprehension will be scored as dichotomous variables, correct or incorrect. The proportion of patients who correctly understand after the standard SCP compared to the proportion who correctly understand after the standard SCP + tailoring + educational support will be analyzed using a two-tailed Z-score test for equality of two proportions at a significance level of P < 0.05. |
At baseline and up to 3 month phone call
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Access to survivorship care for late and long-term side effects
時間枠:At baseline and up to 3 month phone call
|
Will be assessed using the Patients Access Score (PAS). Descriptive statistics will be used to characterize patient access to survivorship care. The difference in mean PAS will be compared between the two arms using a 2 sample t-test. Results will be compared to previous studies, published work, and other historical cohorts. The concordance of urologists' assessment of patients' outcomes with outcomes obtained from patients will be analyzed as the percent of concordant responses, and with unweighted and weighted kappa coefficients. Linear regression models will be used to identify predictors of access to survivorship care. Parsimonious models will be favored due to the relatively small sample size. |
At baseline and up to 3 month phone call
|
|
Decision regret
時間枠:At baseline and up to 3 month phone call
|
Descriptive statistics will be used to characterize decision regret. Results will be compared to previous studies, published work, and other historical cohorts. The concordance of urologists' assessment of patients' outcomes with outcomes obtained from patients will be analyzed as the percent of concordant responses, and with unweighted and weighted kappa coefficients. Parsimonious models will be favored due to the relatively small sample size. |
At baseline and up to 3 month phone call
|
|
Change in decisional conflict
時間枠:At baseline and up to 3 month phone call
|
The two-sample t-test will be used to evaluate the change in the average decisional conflict score between patients in the control arm (standard SCP) and patients in the intervention arm (standard SCP + tailoring + educational supplement). |
At baseline and up to 3 month phone call
|
|
Preparedness for survivorship
時間枠:At baseline and up to 3 month phone call
|
Descriptive statistics will be used to characterize preparedness for survivorship. Results will be compared to previous studies, published work, and other historical cohorts. The concordance of urologists' assessment of patients' outcomes with outcomes obtained from patients will be analyzed as the percent of concordant responses, and with unweighted and weighted kappa coefficients. Parsimonious models will be favored due to the relatively small sample size. |
At baseline and up to 3 month phone call
|
|
Patient self-efficacy
時間枠:At baseline and up to 3 month phone call
|
Descriptive statistics will be used to characterize patient self-efficacy. Results will be compared to previous studies, published work, and other historical cohorts. The concordance of urologists' assessment of patients' outcomes with outcomes obtained from patients will be analyzed as the percent of concordant responses, and with unweighted and weighted kappa coefficients. Parsimonious models will be favored due to the relatively small sample size. |
At baseline and up to 3 month phone call
|
協力者と研究者
スポンサー
捜査官
- 主任研究者:Viraj Master, MD, PhD, FACS、Emory University Hospital/Winship Cancer Institute
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- STUDY00008365
- P30CA138292 (米国 NIH グラント/契約)
- STUDY00008365 (その他の識別子:Emory University Hospital/Winship Cancer Institute)
- NCI-2024-08650 (レジストリ識別子:CTRP (Clinical Trial Reporting Program))
- WINSHIP6368-24 (その他の識別子:Emory University Hospital/Winship Cancer Institute)
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。